Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115639

Apolipoprotein E prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.

N Yamada, I Inoue, M Kawamura, K Harada, Y Watanabe, H Shimano, T Gotoda, M Shimada, K Kohzaki, and T Tsukada

3rd Department of Internal Medicine, University of Tokyo, Japan.

Find articles by Yamada, N. in: PubMed | Google Scholar

3rd Department of Internal Medicine, University of Tokyo, Japan.

Find articles by Inoue, I. in: PubMed | Google Scholar

3rd Department of Internal Medicine, University of Tokyo, Japan.

Find articles by Kawamura, M. in: PubMed | Google Scholar

3rd Department of Internal Medicine, University of Tokyo, Japan.

Find articles by Harada, K. in: PubMed | Google Scholar

3rd Department of Internal Medicine, University of Tokyo, Japan.

Find articles by Watanabe, Y. in: PubMed | Google Scholar

3rd Department of Internal Medicine, University of Tokyo, Japan.

Find articles by Shimano, H. in: PubMed | Google Scholar

3rd Department of Internal Medicine, University of Tokyo, Japan.

Find articles by Gotoda, T. in: PubMed | Google Scholar

3rd Department of Internal Medicine, University of Tokyo, Japan.

Find articles by Shimada, M. in: PubMed | Google Scholar

3rd Department of Internal Medicine, University of Tokyo, Japan.

Find articles by Kohzaki, K. in: PubMed | Google Scholar

3rd Department of Internal Medicine, University of Tokyo, Japan.

Find articles by Tsukada, T. in: PubMed | Google Scholar

Published February 1, 1992 - More info

Published in Volume 89, Issue 2 on February 1, 1992
J Clin Invest. 1992;89(2):706–711. https://doi.org/10.1172/JCI115639.
© 1992 The American Society for Clinical Investigation
Published February 1, 1992 - Version history
View PDF
Abstract

Apo E plays an important role in plasma lipoprotein metabolism through its high affinity binding to cell surface LDL receptor. In the present study, we studied the effects of apo E on the atherogenic process in Watanabe heritable hyperlipidemic rabbits which are deficient in LDL receptor and an animal model for familial hypercholesterolemia. We isolated apo E from plasma of 1% cholesterol-fed rabbits and administered 10 mg of purified apo E intravenously into five Watanabe heritable hyperlipidemic rabbits three times a week from their age of 2.5 months to 11 months for 8.5 months. After sustained administration to apo E, we found a significant reduction in the accumulation of cholesterol ester in aortae (1.55 +/- 0.07 mg/g tissue) as compared to control rabbits (4.32 +/- 0.61 mg/g tissue). Supporting this, the percentage of the surface area of the aorta with macroscopic plaque was remarkably decreased in apo E-treated animals (18.8 +/- 5.1% vs. 38.8 +/- 8.0% in control). Thus, apo E definitely prevented the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 706
page 706
icon of scanned page 707
page 707
icon of scanned page 708
page 708
icon of scanned page 709
page 709
icon of scanned page 710
page 710
icon of scanned page 711
page 711
Version history
  • Version 1 (February 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts